The Department of Health and Human Services transferred $12 million from its Office of Minority Health to offset increasing security expenses for Health Secretary Robert F. Kennedy Jr., according to the Wall Street Journal.
A Washington gathering for Kennedy’s Make America Healthy Again initiative—featuring speakers from the Trump administration—will be financed by corporate sponsors including Walmart and OpenAI, Politico reports.
The Centers for Disease Control and Prevention has not yet begun the process that would allow states to order COVID‑19 vaccines through the Vaccines for Children program, the Wall Street Journal notes.
Senator Rand Paul (R‑KY) is seeking to compel testimony from a longtime former aide of Dr. Anthony Fauci, the former director of the National Institute of Allergy and Infectious Diseases.
Two Democratic senators are urging Kennedy to explain why the Department of Health and Human Services has not released funds earmarked for the Agency for Healthcare Research and Quality, with the September 30 fiscal‑year deadline approaching.
Congressional members are opposing reports that the Trump administration intends to establish a panel of political appointees to approve all National Institutes of Health grants, STAT reports.
Heidi Overton, MD, PhD, President Donald Trump’s nominee to lead the Food and Drug Administration, is scheduled to appear before the Senate Health, Education, Labor and Pensions Committee on Thursday.
A group of senators has introduced legislation aimed at banning the corporate practice of medicine.
Details of the Trump administration’s “Most Favored Nation” drug‑pricing negotiations with pharmaceutical firms have emerged, revealing incentives to raise prices abroad and assurances of protection from Trump‑imposed tariffs, according to the Washington Post.
The Centers for Medicare & Medicaid Services has waived certain Globe and Guard pricing demonstration requirements for select pharmaceutical companies in exchange for additional Medicaid drug rebates, Endpoints News reports.
Medicare officials propose lowering reimbursement rates for laboratory tests, arguing that the program currently pays about 16 % more than private insurers on average for these services.
Josh Denny, who directed the NIH’s All of Us genomics program for six years, has resigned; the agency simultaneously appointed Jonathan Burke to head the Institute of Dental and Craniofacial Research.
A Senate bill designed to require disclosure of where medications are manufactured has seen several key provisions stripped out, ProPublica reports.
Investors are returning to the market for therapies targeting rare diseases, the Wall Street Journal observes.
Also Read
- Economic Frustration Tests Trump’s Standing With Rural Voters, New KFF-AP Poll Finds
- NHS Ghost-Patient Sweep Disproportionately Strips Vulnerable Groups From GP Registers, Warns Medical Community
- STAT+: Drugmakers, biotech VCs show ‘reinvigorated’ interest in osteoporosis treatments
- Tacabrutideg: A Novel BTK Degrader Reshaping the Treatment Landscape for B-Cell Malignancies
